Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind placebo-controlled study of soluble beta-1,3/1,6-glucan (SBG) for chronic diabetic foot ulcers
2008-003636-38Phase 3Completed
- Sponsor
- Biotec Pharmacon ASA
- Start
- Jul 2008
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic foot ulcer (DFU), diabetes mellitus type 1 (T1D) and type 2 diabetes mellitus (T2DM) comparing SBG topical treatment with Placebo topical treatment (2 arms). Primary endpoint: Proportion of patients with target ulcers that heal within 8 weeks. Started Jul 2008; status: completed.
02
Drugs
Imprime PGG
03
Conditions
diabetic foot ulcer (DFU)diabetes mellitus type 1 (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2008-003636-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003636-38.